These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 33191168)
1. The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia. Jabbour E; Kantarjian H Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):63-65. PubMed ID: 33191168 [No Abstract] [Full Text] [Related]
2. Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience. Jalaeikhoo H; Rajaeinejad M; Keyhani M; Zokaasadi M; Dehghani Firoozabadi MM Cancer Med; 2018 Mar; 7(3):594-599. PubMed ID: 29383863 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Two Pediatric-Inspired Regimens to Hyper-CVAD in Hispanic Adolescents and Young Adults With Acute Lymphoblastic Leukemia. Almanza-Huante E; Espinosa-Bautista K; Rangel-Patiño J; Demichelis-Gómez R Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):55-62.e2. PubMed ID: 32893130 [TBL] [Abstract][Full Text] [Related]
4. Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD. Damlaj M; Snnallah M; Bashir R; Eddine IS; Alahmari B; Salama H; Alaskar A; Alhejazi A; Alzahrani M Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):690-696. PubMed ID: 32636149 [TBL] [Abstract][Full Text] [Related]
5. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213 [TBL] [Abstract][Full Text] [Related]
6. Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Guzauskas GF; Villa KF; Vanhove GF; Fisher VL; Veenstra DL J Adolesc Young Adult Oncol; 2017 Mar; 6(1):53-61. PubMed ID: 27779442 [TBL] [Abstract][Full Text] [Related]
7. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284 [TBL] [Abstract][Full Text] [Related]
8. [Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico]. Ramos-Peñafiel CO; Cabrera-García Á; Rozen-Fuller E; González-León G; Balderas C; Kassack-Ipiña JJ; Castellanos-Sinco H; Martínez-Murillo C; Montaño-Figueroa E; Martínez-Tovar A; Olarte-Carrillo I; Santoyo-Sánchez A; Collazo-Jaloma J Rev Peru Med Exp Salud Publica; 2014; 31(3):525-9. PubMed ID: 25418653 [TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055 [TBL] [Abstract][Full Text] [Related]
10. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphoblastic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Büyükçelik A; Yalçin B; Utkan G; Doruk H Cancer; 2004 Sep; 101(5):1100-1; author reply 1101. PubMed ID: 15329922 [No Abstract] [Full Text] [Related]
11. Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study. Erkut N; Akidan O; Selim Batur D; Karabacak V; Sonmez M Chemotherapy; 2018; 63(4):207-213. PubMed ID: 30304722 [TBL] [Abstract][Full Text] [Related]
12. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis. El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194 [TBL] [Abstract][Full Text] [Related]
13. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Rytting ME; Jabbour EJ; Jorgensen JL; Ravandi F; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Borthakur G; Garris R; Wang S; Pierce S; Schroeder K; Kornblau SM; Thomas DA; Cortes JE; O'Brien SM; Kantarjian HM Am J Hematol; 2016 Aug; 91(8):819-23. PubMed ID: 27178680 [TBL] [Abstract][Full Text] [Related]
14. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Garg R; Kantarjian H; Thomas D; Faderl S; Ravandi F; Lovshe D; Pierce S; O'Brien S Cancer; 2009 May; 115(10):2147-54. PubMed ID: 19298009 [TBL] [Abstract][Full Text] [Related]
15. The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience. Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Alghamdi K; Elbjeirami WM Leuk Res; 2017 Sep; 60():58-62. PubMed ID: 28704720 [TBL] [Abstract][Full Text] [Related]
16. [A clinical report on modified Hyper-CVAD regimen in patients with lymphoblastic lymphoma]. Shi W; Shi YK; He XH; Zhou SY; Dong M; Zhang CG; Yang JL; Liu P; Qin Y; Yang S; Gui L Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):978-81. PubMed ID: 20646648 [TBL] [Abstract][Full Text] [Related]
17. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Thomas DA; O'Brien S; Cortes J; Giles FJ; Faderl S; Verstovsek S; Ferrajoli A; Koller C; Beran M; Pierce S; Ha CS; Cabanillas F; Keating MJ; Kantarjian H Blood; 2004 Sep; 104(6):1624-30. PubMed ID: 15178574 [TBL] [Abstract][Full Text] [Related]
18. Feasibility and outcome of the hyper-CVAD regimen in patients with adult acute lymphoblastic leukemia. Portugal RD; Loureiro MM; Garnica M; Pulcheri W; Nucci M Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):52-7. PubMed ID: 25037887 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269 [TBL] [Abstract][Full Text] [Related]
20. Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults. Oh I; Hatano K; Ikeda T; Toda Y; Minakata D; Kawaguchi S; Morita K; Yamamoto C; Ashizawa M; Sato K; Kameda K; Gomyo A; Misaki Y; Kawamura S; Kimura S; Kobayashi H; Sato H; Nakasone H; Ohmine K; Fujiwara S; Kako S; Kanda Y Leuk Res; 2024 Feb; 137():107438. PubMed ID: 38278044 [No Abstract] [Full Text] [Related] [Next] [New Search]